clonazepam
/ Generic mfg.
- LARVOL DELTA
Home
Next
Prev
1 to 25
Of
1718
Go to page
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
August 29, 2026
Endoscopic Salvage of Massive Gastric Bezoar in Severe GI Dysmotility Using Coca-Cola Dissolution and Pathfinder CR-Assisted Evacuation
(ACG 2026)
- "Case Description/ A 33-year-old woman with gastroparesis status post pyloroplasty, colonic inertia requiring diverting ileostomy with multiple revisions, and autonomic dysfunction presented with 3 days of abdominal pain, nausea, and emesis following recent increases in clonazepam and gabapentin. (C) Retroflexed view of the fundus before evacuation demonstrating extensive retained debris prior to evacuation. (D) Retroflexed view of the fundus demonstrating near-complete clearance of gastric contents following intervention."
Gastrointestinal Disorder
September 11, 2026
Timing and Resolution of Talquetamab-Related Dysgeusia in Relapsed/Refractory Multiple Myeloma (RRMM): Longitudinal Waterless Empirical Taste Test and Patient Reported Outcomes Profiles from Talisman
(IMS 2026)
- P2 | "Introduction: In MonumenTAL-1, talquetamab (Tal) elicited durable responses in patients (pts) with RRMM. Dysgeusia by WETT improves as early as 3 months after Tal initiation, with 67% showing improvement after 7 months. Clonazepam prophylaxis did not improve incidence, onset, or resolution of dysgeusia, although low numbers limit definitive conclusions. The highest proportion of pts with dysgeusia/severe dysgeusia by WETT occurred during cycle 3, with the largest changes observed in the sweet, salty, and sour components of the taste profile."
Clinical • Patient reported outcomes • Hematological Malignancies • Multiple Myeloma
September 23, 2026
Management of Non-REM parasomnias: A systematic review of evidence-based treatment approaches.
(PubMed, Sleep Med Rev)
- "Interventions also included melatonin, antidepressants, Z-drugs, topiramate for sleep-related eating disorder, serotonergic precursors in children, and hypnosis...Certainty was very low for most outcomes. High-quality trials with standardized and ideally objective measurements are needed to guide clinical practice."
Journal • Review • CNS Disorders • Sleep Disorder
September 20, 2026
Functional Neurological Disorder Presenting as Psychogenic Non-epileptic Seizures Associated With Recurrent Hemoptysis: A Diagnostic Challenge.
(PubMed, Cureus)
- "The patient was managed with psychotherapy, psychiatric support, selective serotonin reuptake inhibitors (SSRIs), and clonazepam, with tranexamic acid administered during episodes of hemoptysis, resulting in symptomatic improvement. This case highlights an unusual presentation of FND and emphasizes the importance of comprehensive multidisciplinary evaluation in patients with PNES and unexplained hemoptysis. Recognition of this rare association may prevent unnecessary investigations, facilitate timely diagnosis, and enable appropriate psychological and supportive management."
Journal • CNS Disorders • Dermatology • Epilepsy • Hematological Disorders • Immunology • Pain • Psychiatry • Psychosomatic Disorders • Urinary Incontinence • Urology
August 31, 2026
Effect of clonazepam on restless legs syndrome in a multiparous pregnant woman
(MDS Congress 2026)
- No abstract available
Clinical • CNS Disorders • Movement Disorders • Restless Legs Syndrome • Sleep Disorder
September 19, 2026
A longitudinal case report illustrating diagnostic complexity among overlapping sleep-wake phenotypes.
(PubMed, Sleep Med)
- "Positive airway pressure therapy successfully treated sleep disordered breathing while pitolisant and solriamfetol produced the most durable improvement in daytime sleepiness. Together melatonin plus clonazepam reduced parasomnia frequency and severity. Several other agents (including prazosin, sodium oxybate, paroxetine, and modafinil) were tried and discontinued for limited benefit or adverse effects...The observation may justify further study of metabolic and incretin-related pathways in sleep-related eating behaviors. Overall, this case highlights the complexity of overlapping sleep-wake disorders, the need for individualized pharmacologic sequencing, and a potential emerging role for GLP-1 agonists in SRED."
Journal • CNS Disorders • Delayed Sleep Phase Disorder • Excessive Daytime Sleepiness • Genetic Disorders • Obesity • Obstructive Sleep Apnea • Respiratory Diseases • Sleep Apnea • Sleep Disorder • Sleep Wake Cycle Disorder
September 10, 2026
Clonazepam-induced manic episode: A clinical vignette.
(PubMed, Epileptic Disord)
- No abstract available
Journal • CNS Disorders
September 07, 2026
Drug utilisation and adverse drug reaction monitoring in schizophrenic patients: A tertiary care hospital study in India.
(PubMed, Bioinformation)
- "Significant dose variations were noted in commonly used antipsychotics such as risperidone, olanzapine and aripiprazole, as well as benzodiazepines like clonazepam and lorazepam (p<0.001). Atypical antipsychotics predominated due to better tolerability and lower extrapyramidal side effects, highlighting evolving prescribing trends. Thus, structured evidence on drug utilization patterns and variability in dosing, help in optimizing rational prescribing practices in schizophrenia management."
Adverse drug reaction • Journal • CNS Disorders • Psychiatry • Schizophrenia
September 05, 2026
Hallucinogen Persisting Perception Disorder in a Young Adult Case Report.
(PubMed, Case Rep Psychiatry)
- "He was treated with olanzapine, leading to mood stabilization and remission of psychosis. Post treatment, WA continued to experience perceptual disturbances and "visual snow." Medications clonidine and clonazepam were trialed for HPPD...As LSD-assisted therapies continue to be investigated for conditions such as anxiety and depression, recognition and management of persistent adverse effects such as HPPD are becoming increasingly important in both psychiatric and general medical practice. This case demonstrates the limited effectiveness and lack of knowledge on HPPD treatments as well as the need for longitudinal assessments in management."
Journal • Bipolar Disorder • CNS Disorders • Cognitive Disorders • Depression • General Anxiety Disorder • Mental Retardation • Mood Disorders • Psychiatry
August 30, 2026
Less Invasive Rapid Tranquilization in LMIC Emergency Settings: Comparison of Oral Risperidone Plus Clonazepam Versus Intramuscular Haloperidol in a Randomized Trial.
(PubMed, Int J Soc Psychiatry)
- "Therefore, the two regimens should not be considered fully interchangeable in all emergency presentations. We found that oral techniques may enable more humane, less invasive, and culturally acceptable emergency care in LMICs due to the social burden of injectable medication, which typically requires restraint."
Journal • CNS Disorders • Psychiatry • Psychomotor Agitation
August 27, 2026
A retrospective audit of obsessive-compulsive disorder in a tertiary care hospital in Mumbai, India
(WFSBP 2026)
- "Fluoxetine was most commonly used, followed by Clomipramine, Clonazepam, Aripiprazole, and Memantine. This was a retrospective case record analysis of patients with OCD attending the psychiatry outpatient clinic of a single tertiary care hospital. Having established that OCD is often misunderstood, not easily diagnosed and remains an under-diagnosed (severe) psychiatric condition, epidemiological studies are warranted to in populous countries like India."
Retrospective data • CNS Disorders • Mood Disorders • Obsessive-Compulsive Disorder • Psychiatry
August 27, 2026
Neuropsychiatric pleiotropy in 7q11.23 microduplication: A Case Report
(WFSBP 2026)
- "This case supports dup7q11.23 as a rare-variant risk state for a clinically significant ASD– chronic motor tic–OCD phenotype into young adulthood and highlights aripiprazole as a potentially useful option when standard tic-targeting agents are inadequate, warranting systematic study in genetically defined subgroups."
Case report • Clinical • CNS Disorders • Mood Disorders • Movement Disorders • Obsessive-Compulsive Disorder • Psychiatry • Tic Disorders • Tourette Syndrome
August 27, 2026
Neuropsychiatric Manifestations of Prion Disease – a Case Report
(WFSBP 2026)
- "The patient was treated with Olanzapine and Clonazepam 0.5mg BD with no further improvement. In consistence with previously reported cases, our case presented with psychiatric manifestations and later developed neurological manifestations suggestive of CJD with a poor prognosis. Our case highlights the need for a comprehensive neuropsychiatric evaluation for the early detection of neuropsychiatric manifestations of rare illnesses such as CJD"
Case report • Clinical • Alzheimer's Disease • Ataxia • CNS Disorders • Cognitive Disorders • Movement Disorders • Psychiatry • Sleep Disorder
August 27, 2026
When the Gut, Brain, and Heart Lose Synchrony: Autonomic Insights Into PSVT and Panic Symptoms
(WFSBP 2026)
- "Sertraline 50 mg/day and clonazepam 0.5 mg/day produced significant clinical improvement. This case highlights the intricate interplay between cardiac arrhythmia, gastrointestinal dysmotility, and panic symptoms within the gut–brain–heart axis. Recognition of these bidirectional neuro autonomic interactions may improve diagnostic accuracy and support integrated multidisciplinary care involving cardiology, gastroenterology, and psychiatry, ultimately enhancing patient outcomes and quality of life."
CNS Disorders • Mood Disorders
August 27, 2026
Treatment patterns and access among people with epilepsy of childbearing potential in Peru.
(PubMed, Front Neurol)
- "ASMs were categorized according to pregnancy-associated safety profiles as Lower-risk (lamotrigine, levetiracetam, oxcarbazepine, clonazepam, diazepam), Intermediate-High risk (carbamazepine, phenytoin, phenobarbital, topiramate), and Highest-risk (valproic acid). These prescribing patterns likely reflect medication availability rather than clinical preference and highlight the challenges of implementing guideline-recommended epilepsy care in resource-constrained settings. Given the substantial burden of NCC-related epilepsy in this population, improving access to safer and more diverse ASM options may represent an important strategy for reducing treatment inequities among people with epilepsy of childbearing potential."
Journal • CNS Disorders • Epilepsy
August 27, 2026
Use of Corrected QT Cutoffs Derived from Biological Variation to Predict Adverse Events Due to Antipsychotic Drugs: Case Report.
(PubMed, Clin Pract Cases Emerg Med)
- "This case illustrates how results from biological variation studies and a personalized reference level can be helpful to alert physicians earlier of the presence of a potentially toxic condition."
Adverse events • Journal • Acute Coronary Syndrome • Cardiovascular • CNS Disorders • Depression • Pain • Psychiatry • Schizophrenia
August 26, 2026
Intramuscular midazolam versus intravenous clonazepam for prehospital treatment of generalized tonic-clonic seizures: A randomized double-blind non-inferiority trial.
(PubMed, Seizure)
- "IM midazolam was non-inferior to IV clonazepam with respect to treatment success and was associated with a shorter time to seizure cessation while maintaining a comparable safety profile."
Clinical • Head-to-Head • Journal • CNS Disorders • Epilepsy
August 19, 2026
Abemaciclib-Associated Psychosis: A Case Report of a Rare Neuropsychiatric Adverse Effect during Breast Cancer Treatment.
(PubMed, Case Rep Oncol)
- "Her prior treatment had included adjuvant carboplatin and paclitaxel chemotherapy with brachytherapy, and her endocrine therapy was switched from anastrozole to letrozole at the time abemaciclib was added...Treatment with mirtazapine, olanzapine, and clonazepam resulted in the complete resolution of psychotic symptoms, and abemaciclib was permanently discontinued. After approximately 9 months, she was able to discontinue psychiatric medications without relapse of her psychotic symptoms. This case highlights the importance of recognizing rare but serious neuropsychiatric adverse effects of abemaciclib and emphasizes the need for careful monitoring and multidisciplinary management."
Adverse events • Journal • Breast Cancer • CNS Disorders • Endometrial Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Mood Disorders • Oncology • Psychiatry • Solid Tumor • HER-2
July 23, 2026
Stellate Ganglion Block for Refractory Burning Tongue Syndrome: A Case Report
(ASA 2026)
- "She trialed clonazepam but discontinued after severe withdrawal requiring emergency department visits. The patient underwent bilateral stellate ganglion block under fluoroscopic guidance using bupivacaine and dexamethasone. This case highlights stellate ganglion block as a potential treatment for refractory BMS."
Case report • Clinical • CNS Disorders • Gastroesophageal Reflux Disease • Mood Disorders
August 21, 2026
Pharmacological treatments of REM sleep behaviour disorder in synucleinopathies: a systematic review of effectiveness and safety.
(PubMed, Sleep Med)
- "pharmacological treatment of synucleinopathy-associated RBD remains supported by limited and heterogeneous evidence. Larger randomised trials using standardised clinical and vPSG outcomes are needed to clarify efficacy and safety."
Journal • Review • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Dementia • Lewy Body Disease • Movement Disorders • Multiple System Atrophy • Parkinson's Disease • Psychiatry • Sleep Disorder
August 21, 2026
Anhedonia and neuropsychotropics: A pharmacovigilance-pharmacodynamic study.
(PubMed, Therapie)
- "Among neuropsychotropics, serotonin reuptake inhibitors, benzodiazepine anxiolytics and antipsychotics are associated with anhedonia reports. We were unable to find any correlation between anhedonia reports with antidepressants and their direct effects on monoamine transporters."
Adverse events • Journal • PK/PD data • Anesthesia • CNS Disorders • Movement Disorders • Pain • Parkinson's Disease • ROR1
August 18, 2026
Effect of Treatments on Pain and Quality of Life in Individual With Burning Mouth Syndrome
(clinicaltrials.gov)
- P4 | N=50 | Completed | Sponsor: Federal University of Minas Gerais | Active, not recruiting ➔ Completed | N=150 ➔ 50
Enrollment change • HEOR • Trial completion • Pain
August 18, 2026
Short-Lasting Unilateral Neuralgiform Headache Attacks With Conjunctival Injection and Tearing (SUNCT) Across Two Decades: Longitudinal Characterization and Multimodal Management of a Refractory Case.
(PubMed, Cureus)
- "The clinical course demonstrated prominent autonomic symptoms and resistance to multiple pharmacological and surgical interventions, with partial relief achieved only through a multimodal regimen of gabapentin, clonazepam, and indomethacin. This case illustrates the chronic nature of the pathology and emphasizes the importance of long-term longitudinal follow-up and multidisciplinary management in treatment-resistant presentations."
Journal • CNS Disorders • Migraine • Neuralgia • Pain
August 17, 2026
Methionine-Restricted Diet in Sulphite Oxidase Deficiency Associated with a SUOX Variant: Clinical Improvement in a Paediatric Case
(SSIEM 2026)
- "Clonazepam, previously initiated, was discontinued due to adverse effects...Memantine was introduced as symptomatic therapy targeting excitotoxicity via N-methyl-D-aspartate receptor antagonism, while baclofen therapy was continued unchanged...Conclusion In this case, initiation of a methionine-restricted diet in combination with symptomatic therapy was associated with a marked reduction in hypertonia, improvement in postpran-dial vomiting, and significant weight gain. These observations suggest that methionine restriction may attenuate clinical manifestations and support a more favourable disease course in patients with sulphite oxidase deficiency."
Clinical • Pediatrics
August 15, 2026
Standardization of a Protocol to Quantify Benzodiazepines in Human Urine Samples Employing Gas Chromatography-Mass SpectrometryA Green Analytical Chemistry Approach.
(PubMed, ACS Omega)
- "In this study, we standardized a protocol for the detection and quantification of lorazepam (LZ), clonazepam (CZ), and alprazolam (AZ), the short-to-intermediate and long-acting BZDs, without employing any derivatization steps and using gas chromatography-mass spectrometry (GC-MS). Interday and intraday detection precisions were analyzed, which were within agreeable limits. Together, we have developed a green analytical chemistry protocol for the rapid detection of BZDs that can be employed in forensic toxicology and analytical chemistry laboratories for criminal cases, drug overdoses, or drug monitoring."
Journal • CNS Disorders • Epilepsy • Insomnia • Mood Disorders • Psychiatry • Sleep Disorder
1 to 25
Of
1718
Go to page
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69